Marker Therapeutics, Inc. financial data

Symbol
MRKR on Nasdaq
Industry
Pharmaceutical Preparations
Location
2450 Holcombe Blvd, Suite Bcm A, Ms: Bcm251, Houston, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
TAPIMMUNE INC. (to 10/17/2018), TAPIMMUNE INC (to 6/29/2017), GENEMAX CORP (to 6/28/2007), EDUVERSE COM (to 6/17/2002)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 524 % +5.44%
Debt-to-equity 23.6 % -25.5%
Return On Equity -90.4 % -80.2%
Return On Assets -73.1 % -92%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.7M shares +20.3%
Common Stock, Shares, Outstanding 10.7M shares +20.2%
Entity Public Float 48.5M USD +110%
Common Stock, Value, Issued 10.7K USD +20.4%
Weighted Average Number of Shares Outstanding, Basic 8.98M shares +1.94%
Weighted Average Number of Shares Outstanding, Diluted 8.98M shares +1.94%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.5M USD +29.3%
General and Administrative Expense 4.24M USD -43.3%
Operating Income (Loss) -11.1M USD +23.8%
Net Income (Loss) Attributable to Parent -10.7M USD -30.3%
Earnings Per Share, Basic -1.19 USD/shares -26.6%
Earnings Per Share, Diluted -1.19 USD/shares -26.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.2M USD +27%
Assets, Current 22M USD +28.6%
Property, Plant and Equipment, Net 11.7M USD -18.5%
Operating Lease, Right-of-Use Asset 5.33M USD -44.4%
Assets 22M USD +28.6%
Accounts Payable, Current 1.07M USD +10.9%
Employee-related Liabilities, Current 86K USD +50.9%
Liabilities, Current 3.46M USD +12.7%
Operating Lease, Liability, Noncurrent 6.82M USD -38.2%
Liabilities 3.46M USD +12.7%
Retained Earnings (Accumulated Deficit) -447M USD -2.46%
Stockholders' Equity Attributable to Parent 18.6M USD +32.1%
Liabilities and Equity 22M USD +28.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.84M USD +34.8%
Net Cash Provided by (Used in) Financing Activities 49.1K USD -92.1%
Net Cash Provided by (Used in) Investing Activities -113K USD +95.4%
Common Stock, Shares Authorized 30M shares 0%
Common Stock, Shares, Issued 10.7M shares +20.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.2M USD +27%
Deferred Tax Assets, Valuation Allowance 41M USD +3.24%
Deferred Tax Assets, Gross 41M USD +3.24%
Operating Lease, Liability 7.49M USD -36.1%
Depreciation 800K USD -63.6%
Lessee, Operating Lease, Liability, to be Paid 9.23M USD -38.4%
Property, Plant and Equipment, Gross 17.8M USD +30.9%
Operating Lease, Liability, Current 665K USD -2.76%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.29M USD -16.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.25M USD +30.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.74M USD -46.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.18M USD -35.5%
Deferred Tax Assets, Operating Loss Carryforwards 30.7M USD +4.68%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.16M USD -37.9%
Operating Lease, Payments 232K USD -26.6%
Additional Paid in Capital 466M USD +3.38%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 818K USD +42%
Share-based Payment Arrangement, Expense 246K USD -84.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%